USFDA inspection: Biocon Biologics gets 8 observations for Malaysia insulin facility
Bengaluru: Biocon Biologics has announced that the U.S. Food and Drug Administration (FDA) conducted two cGMP inspections at Biocon Sdn. Bhd’s Insulins Manufacturing Facility in Malaysia, encompassing Biologics Drug Substance, Drug Product units and Quality Control laboratories, as well as the Delivery Devices unit.
These inspections were conducted between July 10 and July 20, 2023.
At the conclusion of these inspections, the agency issued a Form 483 with 6 observations for Drug Substance, Drug Product units and Quality Control laboratories as well as 2 observations for the Delivery Devices unit.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Read also: Biocon Biologics Bengaluru facility gets EU GMP certification for Bevacizumab
These observations primarily relate to enhancing operational procedures and strengthening training programs. The inspections did not identify any data integrity breaches or systemic non-compliance.
"We will submit a Corrective and Preventive Action (CAPA) plan to the U.S. FDA in a timely manner and are confident of addressing these observations expeditiously. Biocon Biologics remains committed to global standards of Quality and Compliance.” the company's spokesperson said in a statement.
Read also: Conduct Phase III CT: CDSCO Panel Tells Biocon Biologics Over Anti-cancer Drug Nimutuzumab
Biocon Limited is an Indian biopharmaceutical company headquartered in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the U.S. and Europe. It also has a pipeline of novel assets in immunotherapy under development. Biocon’s biosimilars business is through its subsidiary, Biocon Biologics Ltd.
Read also: Biocon Biologics takes over biosimilars business from Viatris in over 70 countries
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd